文献速递药物不良反应与药物警戒治疗药物监测与药物基因组学肝肾功能剂量调整

中国老年患者万古霉素致急性肾损伤的横断面研究

Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.
PubMed 文献 · Br J Clin Pharmacol · 2018-05-24

该单中心回顾性横断面研究纳入647例接受≥4剂万古霉素治疗的老年住院患者,发现万古霉素致急性肾损伤(VI-AKI)发生率为15.8%。高尿酸血症、机械通气和联用升压药是独立危险因素,较高血清白蛋白为独立保护因素;研究同时发现血肌酐监测不足、治疗药物监测(TDM)使用率低且时机不当。

要点

  • 老年患者VI-AKI发生率为15.8%,高尿酸血症、机械通气、联用升压药为独立危险因素。
  • 较高血清白蛋白为VI-AKI独立保护因素(OR=0.885,P=0.000)。
  • TDM使用率仅32.5%,66.9%的TDM不充分,需加强临床药师投入与监测管理。

核心结论

  • 老年中国患者接受万古霉素治疗时血肌酐监测不足、TDM使用率低且采血时机多不正确。
  • 高尿酸血症、机械通气和联用升压药是VI-AKI独立危险因素,较高血清白蛋白为独立保护因素。

研究设计与样本

  • 单中心回顾性横断面研究,纳入647例接受≥4剂万古霉素治疗的老年住院患者。
  • 排除215例,其中89.3%(192/215)因缺乏血肌酐数据。
  • 比较VI-AKI组与未发生AKI(NO-AKI)组,VI-AKI定义为万古霉素治疗期间或停药后3天内发生AKI。

主要发现

  • VI-AKI发生率为15.8%(102/647)。
  • 32.5%(210/647)的患者在万古霉素治疗期间接受了TDM。
  • 66.9%(424/634)的TDM不充分,仅3.9%(25/634)为适当。
  • 多因素logistic回归显示高尿酸血症OR=3.045(P=0.000)、机械通气OR=1.906(P=0.022)、联用升压药OR=1.919(P=0.027)为独立危险因素。
  • 较高血清白蛋白OR=0.885(P=0.000)为独立保护因素。

关键数值与推荐

  • VI-AKI定义:万古霉素治疗期间或停药后3天内发生AKI。
  • 纳入标准:老年住院患者且接受≥4剂万古霉素治疗。
  • TDM充分性评估:66.9%(424/634)不充分,3.9%(25/634)适当。

临床怎么用

  • 对接受万古霉素治疗的老年患者应加强血肌酐监测和TDM,并确保采血时机正确。
  • 对合并高尿酸血症、接受机械通气或联用升压药的患者应重点关注VI-AKI风险。
  • 建议医院管理者增加临床药师投入,以加强万古霉素专业管理。

局限性

  • 单中心回顾性研究,可能存在选择偏倚和信息偏倚。
  • 215例被排除,其中89.3%因缺乏血肌酐数据,可能影响结果代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The objective of the present study was to investigate the current situation concerning, and risk factors for, vancomycin (VAN)-induced acute kidney injury (VI-AKI) in elderly Chinese patients, to assess outcomes and risk factors in patients who have developed VI-AKI, in order to provide suggestions for improving the prevention and treatment of this condition in these patients. METHOD: We retrospectively identified elderly older inpatients who had received four or more doses of VAN treatment. We compared patients with VI-AKI with those who received VAN treatment and had not developed AKI (NO-AKI). We defined VI-AKI as developing AKI during VAN therapy or within 3 days after withdrawal of VAN. RESULTS: A total of 647 out of 862 elderly inpatients were included in the study. Among those excluded, in 89.3% of cases (192/215) this was because of lack of data on serum creatinine (SCr). Among included patients, 32.5% (210/647) of patients received therapeutic drug monitoring (TDM) during VAN therapy. In 66.9% of cases (424/634), there was insufficient TDM, and in 3.9% (25/634) this was appropriate. A total of 102 patients had confirmed VI-AKI, with an incidence of 15.8% (102/647). Multiple logistic regression analysis revealed that hyperuricaemia [odds ratio (OR) = 3.045; P = 0.000)], mechanical ventilation (OR = 1.906; P = 0.022) and concomitant vasopressor therapy (OR = 1.919; P = 0.027) were independent risk factors for VI-AKI; higher serum albumin (OR = 0.885; P = 0.000) was determined to be an independent protective factor for VI-AKI. CONCLUSIONS: For the elderly Chinese patients treated with VAN, there was insufficient monitoring of SCr, too little use of VAN TDM, and lower rate of patients whose VAN though serum concentrations were not obtained at the correct time. We recommend that hospital managers increase investment in clinical pharmacists, to strengthen professional management. Patients with concomitant hyperuricaemia and on mechanical ventilation and vasopressor therapy should be paid more attention, and a higher serum albumin was determined to be an independent protective factor for VI-AKI.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Pan KM, Wu Y, Chen C, et al. Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study. Br J Clin Pharmacol. 2018. PMID: 29607531. doi:10.1111/bcp.13594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。